
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx Inc demonstrated a positive business outlook with a 21% year-over-year revenue growth in Q3 driven by a 13% increase in volume and a 5% lift in average selling prices (ASPs). The company achieved its highest cash collections in history in October and significantly expanded its sales force by approximately 50%, which is poised to further enhance volume growth over the coming months. Additionally, CareDx reported a solid performance, achieving GAAP net income positivity and raising its revenue guidance, indicative of strong operational momentum.
Bears say
CareDx Inc reported Q3 2025 testing volumes of 50,000, which represented a 13% year-over-year increase but fell short of expectations, indicating a slowdown in growth despite surveillance testing expanding by approximately 20%. The stock has faced downward pressure, trading at only 1.4 times the 2026 revenue estimate of $415 million, which is significantly below historical averages of 3-7 times and far less than competitors in the diagnostics sector valued at 9-10 times. Additionally, the company's reliance on successful commercialization of new diagnostic solutions is uncertain amidst a backdrop of management changes over the past three years, contributing to a cautious outlook on its growth trajectory.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares